131 related articles for article (PubMed ID: 37577994)
1. The value of [18F]FDG PET/CT in avoiding overtreatment of 131l avidity pulmonary metastasis of differentiated thyroid cancer.
Xu Z; Li C; Feng F; Wu S; Wang H; Fu H
Endokrynol Pol; 2023 Aug; ():. PubMed ID: 37577994
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of 2-[
Albano D; Dondi F; Mazzoletti A; Bellini P; Rodella C; Bertagna F
Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943426
[TBL] [Abstract][Full Text] [Related]
5. Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC).
Lodi Rizzini E; Repaci A; Tabacchi E; Zanoni L; Vicennati V; Cavicchi O; Pagotto U; Morganti AG; Fanti S; Monari F
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441364
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
Rizzo A; Perotti G; Zagaria L; Lanni V; Racca M; Palestini N; Salvatori M
Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
[TBL] [Abstract][Full Text] [Related]
7. Iodine-131 SPET/CT and 18F-FDG PET/CT for the identification and localization of mediastinal lymph node metastases from differentiated thyroid carcinoma.
Xu YH; Shen CT; Xue YL; Qiu ZL; Luo QY
Hell J Nucl Med; 2013; 16(3):199-203. PubMed ID: 24251307
[TBL] [Abstract][Full Text] [Related]
8. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
[TBL] [Abstract][Full Text] [Related]
11. Progression free survival related to
Zhu X; Wu S; Yuan X; Wang H; Ma C
Hell J Nucl Med; 2019; 22(2):123-130. PubMed ID: 31273354
[TBL] [Abstract][Full Text] [Related]
12. Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer.
Kim DH; Jung JH; Son SH; Kim CY; Hong CM; Jeong SY; Lee SW; Lee J; Ahn BC
Nucl Med Mol Imaging; 2014 Mar; 48(1):55-62. PubMed ID: 24900139
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of (18)F-FDG PET/CT metabolic parameters in metastatic differentiated thyroid cancers.
Masson-Deshayes S; Schvartz C; Dalban C; Guendouzen S; Pochart JM; Dalac A; Fieffe S; Bruna-Muraille C; Dabakuyo-Yonli TS; Papathanassiou D
Clin Nucl Med; 2015 Jun; 40(6):469-75. PubMed ID: 25899591
[TBL] [Abstract][Full Text] [Related]
14. Lactate Dehydrogenase A is Associated with Elevated FDG Metabolism, Radioiodine Non-avidity, and Poor Prognosis in Differentiated Thyroid Cancer.
Tian T; Dai H; Zhang M; Su M; Chen X; Huang R
Acad Radiol; 2024 Jun; ():. PubMed ID: 38866688
[TBL] [Abstract][Full Text] [Related]
15. Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications.
Morbelli S; Ferrarazzo G; Pomposelli E; Pupo F; Pesce G; Calamia I; Fiz F; Clapasson A; Bauckneht M; Minuto M; Sambuceti G; Giusti M; Bagnasco M
J Endocrinol Invest; 2017 Apr; 40(4):417-424. PubMed ID: 27844413
[TBL] [Abstract][Full Text] [Related]
16. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
Ozkan E; Aras G; Kucuk NO
Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
[TBL] [Abstract][Full Text] [Related]
17. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome).
Ranade R; Kand P; Basu S
Nucl Med Commun; 2015 Oct; 36(10):1014-20. PubMed ID: 26049373
[TBL] [Abstract][Full Text] [Related]
18. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
19.
Nakajo M; Jinguji M; Shinaji T; Tani A; Nakabeppu Y; Nakajo M; Nakajo A; Natsugoe S; Yoshiura T
Br J Radiol; 2019 Feb; 92(1094):20180620. PubMed ID: 30273012
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
